Health

Merck Looks to Join the Obesity Drug Frenzy

Obesity Drugs: Global Sales Could Hit $80 Billion in 2030

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Site feedback:

Take our Survey

By Nacha Cattan

January 4, 2024 at 7:44 PM UTC

This article is for subscribers only.

Merck & Co. is seeking new obesity-fighting drugs called GLP-1s, joining a host of companies angling for a slice of the exploding market.

The drug giant is looking for therapies that provide health benefits for diabetes and other disorders alongside weight loss, Chief Executive Officer Rob Davis said Thursday at an investor conference hosted by Goldman Sachs Group Inc. Merck is seeking opportunities through its own drug development as well as deals, he said.